CD8A and myasthenia gravis: The HLA-A identified in this study belongs to MHC class I molecules, which were upregulated in the group with good prognosis, and the upregulation of MHC class I molecules can increase the efficiency of antigenic peptide presentation; this enhances the function of CD8+ T cells in suppressing both humoral and cellular immunity, so HLA-A may be a potential biomarker for the good prognosis of MG patients.